Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
SENSUS HEALTHCARE, INC.
On November 12, 2026, Sensus Healthcare, Inc. announced via
press release its financial results for the third quarter of 2026. A copy of the press release is filed as Exhibit 99.1 to this
Current Report on Form 8-K and incorporated herein by reference.
The press release makes reference to certain non-GAAP financial
measures. A reconciliation of the non-GAAP financial measures and other financial information is provided in the press release.
The information furnished under Item 2.02, including in Exhibit
99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be
deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific
reference in such filing.
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
Exhibit 99.1
Sensus Healthcare Reports Third Quarter
2026 Financial Results and Business Highlights
Commercial Momentum Builds with Broader
Physician Engagement and Customer Adoption
New Dermatology Group Relationships Support
Customer Expansion and Diversification Strategy
Increasing Patient Awareness and International
Commercial Activities Create Additional Growth Opportunities
BOCA RATON, Fla., November 12, 2026 – Sensus Healthcare,
Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological
and non-oncological skin conditions, today announced financial results and business highlights for the three months ended September
30, 2026.
Highlights included:
| ● | Revenues of $6.0 million compared with $6.9 million in the third quarter
of 2025, reflecting a product mix of lower-priced SRT-100 systems and the absence of sales to a historically large customer. |
| ● | Gross profit increased to $3.3 million from $2.7 million in the third
quarter of 2025 and gross margin improved to 55% from 39.1% in the prior-year period. |
| ● | Shipped 26 systems, including eight carried over from the second quarter
of 2026 due to financing approval timing, compared with 16 in the prior-year period. Excluding those eight systems, 18 systems
were shipped during the quarter, compared with six shipments to customers other than the Company’s historically largest customer
in the third quarter of 2025. |
| ● | Continued physician education initiatives and expanded customer relationships,
including initial system purchases by two large private equity-backed dermatology groups. |
| ● | Launched TreatSkinCancer.com, a consumer education resource designed
to increase awareness of skin cancer treatment options, complementing the Company’s ongoing physician education initiatives. |
| ● | Advanced international market-development activities across Asia-Pacific,
including Australia, New Zealand, China and Hong Kong. |
| ● | Subsequent to quarter end, placed the Company’s 1,000th SRT
system, marking an important commercial milestone. |
Management Commentary
"Our third quarter results reflect continued progress in
building a broader, more diversified customer base and advancing our business toward sustainable profitability," said Joseph
Sardano, Chairman and Chief Executive Officer. “With dedicated reimbursement codes now in effect, our conversations with
physicians are increasingly focused on how to bring SRT into their practices.
“Our vision is to make SRT a more widely understood and
accessible non-invasive treatment option for appropriate patients with non-melanoma skin cancer. We are expanding physician education
and patient awareness, including through TreatSkinCancer.com, while pursuing opportunities internationally and developing additional
revenue streams tied to system utilization, software and services. The recent sale of our 1,000th SRT system is a milestone I am
particularly proud of.
“We have spent years advancing the technology and growing
our installed base. Today, we have a reimbursement framework that we believe can support broader adoption and a more scalable business.
Our focus is on converting these opportunities into sales, increasing utilization and building a more diversified, sustainably
profitable business,” concluded Sardano.
Third Quarter 2026 Financial Results
Revenues were $6.0 million compared with $6.9 million for the
quarter ended September 30, 2025, a decrease of $0.9 million, or 13.0%. The revenue decrease primarily reflected a shift in product
mix toward lower-priced SRT-100 systems versus higher-priced SRT-100 Vision systems, resulting in a lower average selling price
per unit, as well as the absence of sales to a historically large customer. In addition, three systems shipped during the quarter
were under the Fair Deal Agreement program and rental arrangements compared to zero in the prior year period, for which revenue
is recognized over the term of the agreement rather than at the time of shipment.
Unit shipments increased year-over-year to 26 systems, including
eight carried over from the second quarter of 2026, compared with 16 systems in the prior-year period.
Cost of sales was $2.7 million compared to $4.2 million for
the quarter ended September 30, 2025, a decrease of $1.5 million, or 35.7%. The decrease in cost of sales was primarily related
to the product mix, including a higher proportion of SRT-100 units shipped compared to SRT-100 Vision units shipped, as SRT-100
units have a lower average cost per unit.
Gross profit was $3.3 million compared to $2.7 million for the
three months ended September 30, 2025, an increase of $0.6 million, or 22.2%. Overall gross profit percentage was 55%, compared
to 39.1% in the corresponding period in 2025. The increase in gross profit and margin was primarily driven by product mix, including
a higher proportion of shipments of higher-margin SRT-100 units compared to lower-margin SRT-100 Vision units.
General and administrative expense was $2.3 million compared
to $1.9 million for the quarter ended September 30, 2025, an increase of $0.4 million, or 21.1%. The net increase in general and
administrative expense was primarily due to higher legal and professional fees offset by reduction of insurance cost.
Selling and marketing expense was $1.5 million, flat with the
third quarter of 2025.
Research and development expense was $1.1 million compared to
$1.8 million for the quarter ended September 30, 2025, a decrease of $0.7 million, or 38.9%. The decrease was primarily due to
a reduction in lobbying cost and reduced headcount.
Other income of $0.1 million and $0.2 million for the quarters
ended September 30, 2026 and 2025, respectively, relates primarily to interest income.
Net loss was $1.5 million, or $0.09 per share, compared with
net loss of $0.9 million, or $0.06 per share, for the three months ended September 30, 2025.
Adjusted EBITDA was a negative $1.5 million, compared with negative
$2.4 million for the third quarter of 2025. Adjusted EBITDA, a non-GAAP financial measure, is defined as earnings before interest,
taxes, depreciation, amortization and stock-compensation expense. Please see below for a reconciliation between GAAP and non-GAAP
financial measures, and the reasons these non-GAAP financial measures are provided.
Cash, restricted cash and cash equivalents were $12.9 million
as of September 30, 2026, compared with $15.2 million as of June 30, 2026. The Company had no outstanding borrowings under its
revolving line of credit at September 30, 2026. Prepaid inventory was zero compared with $0.6 million as of June 30, 2026. Inventories
were $18.0 million compared with $18.5 million as of June 30, 2026.
Conference Call and Webcast
Sensus Healthcare will host an investment community conference
call today beginning at 4:30 p.m. Eastern time during which management will discuss these financial results, provide a business
update and answer questions.
Participants are encouraged to pre-register for the conference
call using this link to receive a unique dial-in number to bypass the live operator. Participants may pre-register at
any time, including up to and after the call start time. Those unable to pre-register can access the conference call by dialing
844-481-2811 (U.S. and Canada Toll Free) or 412-317-0676 (International). Please ask the operator to be connected to the Sensus
Healthcare conference call.
The call will be webcast live and can be accessed at this link or
in the Investor Relations section of the Company’s website at www.sensushealthcare.com.
Use of Non-GAAP Financial Information
This press release contains supplemental financial information
determined by methods other than in accordance with accounting principles generally accepted in the United States (GAAP). Sensus
Healthcare management understands that investors and analysts use Adjusted EBITDA, a non-GAAP financial measure, in analyzing the
Company’s performance. Adjusted EBITDA should not be considered a substitute for GAAP basis measures, nor should it be viewed
as a substitute for operating results determined in accordance with GAAP. Non-GAAP financial measures are not formally defined
by GAAP, and other entities may use calculation methods that differ from those used by Sensus Healthcare. As a complement to GAAP
financial measures, management believes that Adjusted EBITDA assists investors who follow the practice of some investment analysts
who adjust GAAP financial measures to exclude items that may obscure underlying performance and distort comparability. A reconciliation
of the GAAP net loss to Adjusted EBITDA is provided in the schedule below.
SENSUS HEALTHCARE,
INC.
GAAP TO NON-GAAP
RECONCILIATION
(unaudited)
| | |
For the Three Months Ended September 30, | | |
For the Nine Months Ended September 30, | |
| (in thousands) | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| Net loss, as reported | |
$ | (1,493 | ) | |
$ | (943 | ) | |
$ | (12,868 | ) | |
$ | (4,552 | ) |
| Add: | |
| | | |
| | | |
| | | |
| | |
| Depreciation | |
| 81 | | |
| 98 | | |
| 263 | | |
| 283 | |
| Stock compensation expense | |
| 70 | | |
| 73 | | |
| 209 | | |
| 219 | |
| Income tax (benefit) expense | |
| — | | |
| (1,466 | ) | |
| 4,079 | | |
| (2,079 | ) |
| Interest income, net | |
| (126 | ) | |
| (160 | ) | |
| (368 | ) | |
| (528 | ) |
| Adjusted EBITDA, non-GAAP | |
$ | (1,468 | ) | |
$ | (2,398 | ) | |
$ | (8,685 | ) | |
$ | (6,657 | ) |
About Sensus Healthcare
Sensus Healthcare, Inc. is a global pioneer in the development
and delivery of non-invasive treatments for skin cancer and keloids. Leveraging its cutting-edge superficial radiotherapy (SRT
and IG-SRT) technology, the company provides healthcare providers with a highly effective, patient-centric treatment platform.
With a dedication to driving innovation in radiation oncology, Sensus Healthcare offers solutions that are safe, precise, and adaptable
to a variety of clinical settings. For more information, please visit www.sensushealthcare.com.
Forward-Looking Statements
This press release includes statements that are, or may be deemed,
“forward-looking statements.” In some cases, these statements can be identified by the use of forward-looking terminology
such as “believes,” “estimates,” “anticipates,” “expects,” “plans,”
“intends,” “may,” “could,” “might,” “will,” “should,” “approximately,”
or “potential,” or negative or other variations of those terms or comparable terminology, although not all forward-looking
statements contain these words. Forward-looking statements involve risks and uncertainties because they relate to events, developments,
and circumstances relating to Sensus Healthcare, Inc., our industry, and/or general economic or other conditions that may or may
not occur in the future or may occur on longer or shorter timelines or to a greater or lesser degree than anticipated. In addition,
even if future events, developments and circumstances are consistent with the forward-looking statements contained in this release,
they may not be predictive of results or developments in future periods. Although we believe that we have a reasonable basis for
each forward-looking statement contained in this release, forward-looking statements are not guarantees of future performance,
and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate,
may differ materially from the forward-looking statements contained in this release as a result of the following factors, among
others: the level and availability of government and/or third party payor reimbursement for clinical procedures using our products,
and the willingness of healthcare providers to purchase our products if the level of reimbursement declines; concentration of our
customers in the U.S.; the development by others of new products, treatments, or technologies that render our technology partially
or wholly obsolete; the regulatory requirements applicable to us and our competitors; our ability to efficiently manage our manufacturing
processes and costs; the risks arising from doing business in China and other foreign countries, including ongoing geopolitical
tensions between the U.S. and China; legislation, regulation, or other governmental action that affects our products, taxes, international
trade regulation (including the possibility of tariffs and fluctuations in tariffs on equipment we export or materials we import),
or other aspects of our business; the performance of the Company’s information technology systems and its ability to maintain
data security; the possibility that inflationary pressures continue to impact our sales; our ability to obtain and maintain the
intellectual property needed to adequately protect our products, and our ability to avoid infringing or otherwise violating the
intellectual property rights of third parties; and other risks described from time to time in our filings with the Securities and
Exchange Commission. To date, geopolitical uncertainties have not had any significant impact on our business, but we continue to
monitor developments and will address them in future disclosures, if applicable. Any forward-looking statements that we make in
this release speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events
or circumstances after the date this release is filed, except as may be required by applicable law.
Investor Relations Contact
Leigh Salvo
New Street Investor Relations
leigh@newstreetir.com
SENSUS HEALTHCARE, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
| | |
For the Three Months Ended September 30, | | |
For the Nine Months Ended September 30, | |
| (in thousands, except shares and per share data) | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| | |
(unaudited) | | |
(unaudited) | | |
(unaudited) | | |
(unaudited) | |
| Revenues | |
$ | 5,995 | | |
$ | 6,884 | | |
$ | 11,679 | | |
$ | 22,543 | |
| Cost of sales | |
| 2,707 | | |
| 4,171 | | |
| 6,632 | | |
| 12,573 | |
| Gross profit | |
| 3,288 | | |
| 2,713 | | |
| 5,047 | | |
| 9,970 | |
| Operating expenses: | |
| | | |
| | | |
| | | |
| | |
| General and administrative | |
| 2,253 | | |
| 1,917 | | |
| 6,079 | | |
| 6,111 | |
| Selling and marketing | |
| 1,548 | | |
| 1,546 | | |
| 4,319 | | |
| 5,122 | |
| Research and development | |
| 1,106 | | |
| 1,819 | | |
| 3,806 | | |
| 5,896 | |
| Total operating expenses | |
| 4,907 | | |
| 5,282 | | |
| 14,204 | | |
| 17,129 | |
| Loss from operations | |
| (1,619 | ) | |
| (2,569 | ) | |
| (9,157 | ) | |
| (7,159 | ) |
| Other income: | |
| | | |
| | | |
| | | |
| | |
| Interest income, net | |
| 126 | | |
| 160 | | |
| 368 | | |
| 528 | |
| Other income, net | |
| 126 | | |
| 160 | | |
| 368 | | |
| 528 | |
| Loss before income tax | |
| (1,493 | ) | |
| (2,409 | ) | |
| (8,789 | ) | |
| (6,631 | ) |
| Provision for (benefit from) income taxes | |
| — | | |
| (1,466 | ) | |
| 4,079 | | |
| (2,079 | ) |
| Net loss | |
$ | (1,493 | ) | |
$ | (943 | ) | |
$ | (12,868 | ) | |
$ | (4,552 | ) |
| Net loss per share – basic | |
$ | (0.09 | ) | |
$ | (0.06 | ) | |
$ | (0.78 | ) | |
$ | (0.28 | ) |
| diluted | |
$ | (0.09 | ) | |
$ | (0.06 | ) | |
$ | (0.78 | ) | |
$ | (0.28 | ) |
| Weighted average number of shares used in computing | |
| | | |
| | | |
| | | |
| | |
| net loss per share – basic | |
| 16,462,059 | | |
| 16,320,036 | | |
| 16,462,255 | | |
| 16,327,233 | |
| diluted | |
| 16,462,059 | | |
| 16,320,036 | | |
| 16,462,255 | | |
| 16,327,233 | |
SENSUS HEALTHCARE, INC.
CONSOLIDATED BALANCE SHEETS
| | |
As of September 30, | | |
As of December 31, | |
| (in thousands, except shares and per share data) | |
2026 | | |
2025 | |
| | |
(unaudited) | | |
| |
| Assets | |
| | | |
| | |
| Current assets | |
| | | |
| | |
| Cash, restricted cash, and cash equivalents | |
$ | 12,920 | | |
$ | 22,083 | |
| Accounts receivable, net | |
| 1,403 | | |
| 6,041 | |
| Inventories | |
| 17,965 | | |
| 14,563 | |
| Prepaid inventory | |
| — | | |
| 1,522 | |
| Notes receivable, current portion | |
| 609 | | |
| — | |
| Other current assets | |
| 1,687 | | |
| 1683 | |
| Total current assets | |
| 34,584 | | |
| 45,892 | |
| Property and equipment, net | |
| 2,662 | | |
| 1,976 | |
| Deferred tax asset | |
| — | | |
| 4,079 | |
| Operating lease right-of-use assets, net | |
| 265 | | |
| 452 | |
| Notes receivable, net of current portion | |
| 2,731 | | |
| 352 | |
| Other noncurrent assets | |
| 309 | | |
| 288 | |
| Total assets | |
$ | 40,551 | | |
$ | 53,039 | |
| Liabilities and stockholders’ equity | |
| | | |
| | |
| Current liabilities | |
| | | |
| | |
| Accounts payable and accrued expenses | |
$ | 3,746 | | |
$ | 3,343 | |
| Product warranties | |
| 302 | | |
| 275 | |
| Operating lease liabilities, current portion | |
| 278 | | |
| 262 | |
| Deferred revenue, current portion | |
| 785 | | |
| 842 | |
| Total current liabilities | |
| 5,111 | | |
| 4,722 | |
| Operating lease liabilities, net of current portion | |
| — | | |
| 209 | |
| Deferred revenue, net of current portion | |
| — | | |
| 10 | |
| Total liabilities | |
| 5,111 | | |
| 4,941 | |
| Commitments and contingencies | |
| | | |
| | |
| Stockholders’ equity | |
| | | |
| | |
| Preferred stock, 5,000,000 shares authorized and none issued and outstanding | |
| — | | |
| — | |
| Common stock, $0.01 par value – 50,000,000 authorized; 17,055,095 issued and 16,462,059 outstanding at September 30, 2026; 17,056,845 issued and 16,463,809 outstanding at December 31, 2025 | |
| 169 | | |
| 169 | |
| Additional paid-in capital | |
| 46,300 | | |
| 46,090 | |
| Treasury stock, 593,036 shares at cost, at September 30, 2026 and December 31, 2025 | |
| (3,876 | ) | |
| (3,876 | ) |
| (Accumulated deficit) retained earnings | |
| (7,153 | ) | |
| 5,715 | |
| Total stockholders’ equity | |
| 35,440 | | |
| 48,098 | |
| Total liabilities and stockholders’ equity | |
$ | 40,551 | | |
$ | 53,039 | |